Search

Your search keyword '"Rumaiza H. Al-Yafeai"' showing total 2 results
Start Over Author "Rumaiza H. Al-Yafeai" Topic consensus
2 results on '"Rumaiza H. Al-Yafeai"'

1. Saudi consensus recommendations on the management of Neuromyelitis Optica Spectrum Disorders (NMOSD)

Author

Eslam Shosha, Salman A. Aljarallah, Norah Al Fugham, Ahmed H. Al-Jedai, Majed M. Al Luqmani, Yaser M. Al Malik, Hajer Y. Al Mudaiheem, Hessa S. Al Otaibi, Faisal Y. Al Thekair, Ibtisam A. Al Thubaiti, Rumaiza H. Al Yafeai, Nabila S. Ben Slimane, Reem F. Bunyan, Edward J. Cupler, Sultan M. Mubarki, Jameelah A. Saeedi, and Mohammad A. Al Jumah

Subjects
Aquaporin 4, Consensus, Neurology, Interleukin-6, Neuromyelitis Optica, Saudi Arabia, Humans, Neurology (clinical), General Medicine, Biomarkers, Autoantibodies
Abstract

This article focuses on the diagnosis and management of neuromyelitis optica spectrum disorder (NMOSD). NMOSD is an autoimmune, demyelinating condition characterized by inflammation of the optic nerve and/or the spinal cord, with symptoms that can range from mild impairment of movement to paralysis. The newly approved diagnostic criteria have improved the accuracy of NMOSD diagnosis. The management of NMOSD is under major revolution due to the many new therapeutic options. The role of the antibodies directed at aquaporin-4 (AQP4) has materialized as a biomarker for NMOSD. Several new treatments that target variable aspects in immunopathology such as IL-6, complement, or depletion of B cells are emerging. The management of AQP4-negative patients remains challenging.

Published
2022
Full Text
View/download PDF

2. Saudi Consensus Recommendations on the Management of Multiple Sclerosis: Disease-Modifying Therapies and Management of Relapses

Author

Yaser M. Al Malik, Ibtisam A. Al Thubaiti, Maha A. AlAmmari, Norah Al Fugham, Eman N. Ali, Dema A. Alissa, Salman A. Aljarallah, Ahmed H. Al-Jedai, Maeed A. AlKathiri, Mona M. AlKhawajah, Mousa A. Almejally, Hajer Y. Al-Mudaiheem, Hessa S. Al Otaibi, Ghadah H. AlTowaijri, Rumaiza H. Al Yafeai, Mohammed A. Babakkor, Saeed A. Bohlega, Reem F. Bunyan, Edward J. Cupler, Mohammed Hakami, Abid M. Kareem, Amr M. Khardaly, Seraj Makkawi, Leena H. Saeed, Jameelah A. Saeedi, Eslam Shosha, and Mohammad A. Al Jumah

Subjects
multiple sclerosis, relapses, Saudi, consensus, disease-modifying therapy, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571
Abstract

For the past 10 years, disease-modifying therapy (DMT) options for multiple sclerosis (MS) have grown remarkably where DMTs have been shown to reduce the risk of MS relapses. MS patients are advised to begin treatment with a DMT shortly after diagnosis to limit the possibility of disease progression over time. While patients with radiologically isolated syndrome do not require pharmacologic treatment, high-risk patients with clinically isolated syndrome are advised to start DMTs. This article provides evidence-based recommendations for DMT use in MS management, helping healthcare practitioners advise patients on treatment decisions. We aim to provide recommendations for the management of acute MS relapses. The recommendations herein were developed following the gathering of a panel of experts after evaluating international guidelines, and the latest evidence was collected through a comprehensive literature review.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results